188 related articles for article (PubMed ID: 18702389)
1. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation.
Jose L; Binila C; Chandy SJ; Mathews JE; Mathews KP
J Assoc Physicians India; 2008 Apr; 56():250-2. PubMed ID: 18702389
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
3. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
4. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
[TBL] [Abstract][Full Text] [Related]
6. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
[TBL] [Abstract][Full Text] [Related]
7. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
[TBL] [Abstract][Full Text] [Related]
8. Retroperitoneal haematoma in a patient treated with acenocoumarol, phenytoin and paroxetine.
Abad-Santos F; Carcas AJ; F-Capitán C; Frias J
Clin Lab Haematol; 1995 Jun; 17(2):195-7. PubMed ID: 8536426
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
Schalekamp T; Boink GJ; Visser LE; Stricker BH; de Boer A; Klungel OH
Clin Pharmacol Ther; 2006 Jun; 79(6):511-20. PubMed ID: 16765138
[No Abstract] [Full Text] [Related]
10. Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.
André-Kerneïs E; Leroy-Matheron C; Gouault-Heilmann M
Blood Coagul Fibrinolysis; 2003 Dec; 14(8):761-4. PubMed ID: 14614357
[TBL] [Abstract][Full Text] [Related]
11. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
Gschwind L; Rollason V; Boehlen F; Rebsamen M; Combescure C; Grünenwald M; Matthey A; Bonnabry P; Dayer P; Desmeules JA
Pharmacogenomics; 2013 May; 14(7):745-53. PubMed ID: 23651023
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis.
De T; Christopher R; Nagaraja D
Thromb Res; 2014 May; 133(5):729-35. PubMed ID: 24530212
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
Takahashi H; Wilkinson GR; Padrini R; Echizen H
Clin Pharmacol Ther; 2004 May; 75(5):376-80. PubMed ID: 15116049
[No Abstract] [Full Text] [Related]
15. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
[TBL] [Abstract][Full Text] [Related]
16. The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery.
Beinema MJ; de Jong PH; Salden HJ; van Wijnen M; van der Meer J; Brouwers JR
Mol Diagn Ther; 2007; 11(2):123-8. PubMed ID: 17397249
[TBL] [Abstract][Full Text] [Related]
17. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.
Citerio G; Nobili A; Airoldi L; Pastorelli R; Patruno A
Neurology; 2003 Apr; 60(8):1395-6. PubMed ID: 12707459
[No Abstract] [Full Text] [Related]
18. Retrospective analyses of acenocoumarol doses and bleeding complications in patients with wild type or variant cytochrome P450 CYP2C9 alleles.
Mark L; Marki-Zay J; Paragh G; Katona A
Thromb Haemost; 2005 Feb; 93(2):396-7. PubMed ID: 15711768
[No Abstract] [Full Text] [Related]
19. Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India.
Ramasamy K; Narayan SK; Chanolean S; Chandrasekaran A
Neurol India; 2007; 55(4):408-9. PubMed ID: 18040121
[TBL] [Abstract][Full Text] [Related]
20. Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9.
Zarza J
Thromb Haemost; 2003 Jul; 90(1):161-2. PubMed ID: 12876643
[No Abstract] [Full Text] [Related]
[Next] [New Search]
